Dong Jianyong, Han Deting, Wang Desheng, Lu Huijun, Wang Xiaoliang
Gaoxin Branch of Jinan Stomatological Hospital.
Shandong University of Traditional Chinese Medicine, Jinan, China.
Medicine (Baltimore). 2020 Oct 2;99(40):e22596. doi: 10.1097/MD.0000000000022596.
The pathophysiologic of vascular malformations is still unclear, and the treatment of vascular malformations is a challenge. With improvement in the understanding of pathogenesis of vascular malformations, sirolimus has been a promising and effective treatment. As so far, there is absent convincing evidence to confirm the efficacy of sirolimus for vascular malformations. The purpose of this study was to evaluate the effectiveness and safety of sirolimus in the treatment of vascular malformations.
The literatures about the management of vascular malformations with sirolimus would be searched from databases of MEDLINE, EMBASE, PubMed, Web of Science, Clinicaltrials.org., Cochrane Library, China Biology Medicine Database (CBM), Wan Fang Database, China National Knowledge Infrastructure Database (CNKI), and VIP Science Technology Periodical Database. We will search each database from inception or 1995 to August 20, 2020. Two researchers worked independently on literature selection, data extraction and quality assessment. The efficacy and safety of sirolimus in the treatment of vascular malformations were the main outcomes. Adverse events after sirolimus were evaluated as the secondary outcomes. The included studies will be analyzed by Review Manager 5.3. If the results are applicable, meta-analysis would also be performed.
The study will evaluate the efficacy and safety of sirolimus in the treatment of vascular malformations based on current evidence.
The conclusion of this study will provide more reliable, evidence-based data for the use of sirolimus in the treatment of vascular malformations.
CRD42020167881.
血管畸形的病理生理学仍不清楚,血管畸形的治疗是一项挑战。随着对血管畸形发病机制认识的提高,西罗莫司已成为一种有前景且有效的治疗方法。到目前为止,尚无令人信服的证据证实西罗莫司对血管畸形的疗效。本研究的目的是评估西罗莫司治疗血管畸形的有效性和安全性。
从MEDLINE、EMBASE、PubMed、Web of Science、Clinicaltrials.org.、Cochrane图书馆、中国生物医学数据库(CBM)、万方数据库、中国知网数据库(CNKI)和维普科技期刊数据库中检索关于使用西罗莫司治疗血管畸形的文献。我们将检索每个数据库自创建或1995年至2020年8月20日的文献。两名研究人员独立进行文献筛选、数据提取和质量评估。西罗莫司治疗血管畸形的有效性和安全性是主要结局。西罗莫司治疗后的不良事件作为次要结局进行评估。纳入的研究将使用Review Manager 5.3进行分析。如果结果适用,还将进行荟萃分析。
本研究将基于现有证据评估西罗莫司治疗血管畸形的有效性和安全性。
本研究的结论将为西罗莫司治疗血管畸形的应用提供更可靠的循证数据。
PROSPERO注册号:CRD42020167881。